In short
MK-4318 is an investigational oral medicine being studied for acute and chronic pain. Two completed Phase 1 trials in healthy adults have assessed its safety, tolerability, and how the body processes it (pharmacokinetics). Across the two trials, 64 participants received single or multiple oral doses of MK-4318.
Key points
- MK-4318 is an investigational oral medicine studied for acute and chronic pain.
- Two Phase 1 trials in healthy adults have been completed.
- The single-dose trial enrolled 32 participants and tested a 600 mg oral dose.
- The multiple-dose trial enrolled 32 participants and tested repeated 400 mg oral doses.
- Both trials measured adverse events and pharmacokinetics, including how much of the drug reaches the blood.
- MK-4318 is classified in the nervous system diseases therapeutic area.
What is MK-4318?
MK-4318 is an investigational oral medicine studied for acute and chronic pain. It is classified in the therapeutic area of nervous system diseases, according to the CTIS product records of the trials. No marketing authorisation information is available in the provided sources, which indicates that MK-4318 is still in the research stage.
How does MK-4318 work?
The available trial records do not describe the mechanism of action of MK-4318. The studies focused on measuring safety, tolerability, and pharmacokinetics — how the body absorbs, distributes, and eliminates the substance — rather than on explaining its molecular target.
Which conditions is MK-4318 studied for?
- Acute and chronic pain — the single-dose study listed this as the condition under investigation.
- Pain — the multiple-dose study listed pain as the condition under investigation.
How is MK-4318 given?
MK-4318 is given by mouth as a capsule. In the single-dose trial, participants received a 600 mg oral dose. In the multiple-dose trial, participants received repeated 400 mg oral doses. The placebo arms contained microcrystalline cellulose, lactose monohydrate, and magnesium stearate (non-bovine).
What do the clinical trials show?
Two Phase 1 trials of MK-4318 have been completed. Both were conducted in healthy adult participants and focused on safety, tolerability, and pharmacokinetics.
What are the trials measuring?
Both trials measured the number or percentage of participants who experienced adverse events and those who discontinued due to adverse events. They also measured pharmacokinetic parameters, including the maximum plasma concentration (Cmax), the time to reach it (Tmax), and the area under the plasma concentration-time curve (AUC), which reflects total drug exposure over time.
Who can take part in these trials?
Both trials enrolled healthy adult participants. The single-dose study enrolled 32 participants, and the multiple-dose study also enrolled 32 participants.
What side effects are known?
No side effect information is available from the provided sources. The trials measured adverse events, but their results are not included in the registry data provided.